Specific reasons
On March 30th, 20021year, Fujian Medical Insurance Bureau issued the No.4 document of Fujian Medicine Mining Center, which included Tasly's unique product Compound Danshen Dripping Pills in the second batch of key monitored drugs. However, it is generally believed in the industry that Fujian medical insurance plays an important role in the national medical insurance policy, which will lead National Health Commission to follow suit all over the country, which will be a devastating blow to Tasly. There is also the coenzyme of Shuanglu Pharmaceutical. Except for the compound Danshen series, Tasly can't support other products that maintain the status quo, and the later trend will also go out of the trend that Shuanglu continues to bottom out. Interested parties can compare the stock price trend and verify the accuracy of the news by themselves.
superiority
In the past, the company was an excellent company, with unique resources, which could bring sustained and stable profits and cash flow to the company, that is, a stable foundation.
The current stock price fully reflects all kinds of bad and negative information, and the market gives extreme expectations and pessimistic stock prices. The current share price still has certain attraction and investment value.
The company's fundamentals show signs of improvement, and the fundamental inflection point has appeared, which will soon promote the value repair.
Tasly Group, founded in 1994, is a high-tech enterprise group with comprehensive internationalization as the guide, big health industry as the main line, big biomedical industry as the core, biomedical engineering as the cooperation, and health care industry and medical rehabilitation, health preservation and health management services as the two wings.